Display Settings:

Format

Send to:

Choose Destination
    Am J Trop Med Hyg. 2009 Feb;80(2):218-27.

    Genetic variation among Plasmodium vivax isolates adapted to non-human primates and the implication for vaccine development.

    Source

    Global Health Infectious Disease Research, Department of Global Health, College of Public Health, University of South Florida, Tampa, Florida 33612, USA.

    Abstract

    Plasmodium vivax Duffy binding protein (DBP) is vital for parasite development, thereby making this molecule a good vaccine candidate. Preclinical development of a P. vivax vaccine often involves use of primate models prior to testing efficacy in humans, but primate isolates are poorly characterized. We analyzed the complete gene coding for the DBP in several P. vivax isolates that are used for experimental primate infections and compared these sequences with the Salvador I DBP isolate, which is being used for vaccine development. Our results affirm that primate-adapted isolates are genetically similar to P. vivax circulating in humans, but variability is greatest in the putative target of protective antibodies. In addition, some P. vivax isolates contain multiple genetically different clones. Testing a DBP vaccine may therefore be complicated by heterogeneity and diversity of the P. vivax isolates available for in vivo challenge.

    PMID:
    19190217
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2760840
    Free PMC Article

    Images from this publication.See all images (4) Free text

    Figure 2
    Figure 4
    Figure 1
    Figure 3

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk